Simone L. Cree

Simone L. Cree

Auto-generated profile, based on publicly available information

Simone L. Cree

Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ECEng Wee Chua
Eng Wee Chua
SCSimone L. Cree
Simone L. Cree
KTKim N. T. Ton
Kim N. T. Ton
KLKlaus Lehnert
Klaus Lehnert
PSPhillip Shepherd
Phillip Shepherd
MKMartin Alexander Kennedy
Martin Alexander Kennedy
Whole-exome sequencing (WES) has been widely used for analysis of human genetic diseases, but its value for the pharmacogenomic profiling of individuals is not well studied. Initially, we performed an in-depth evaluation of the accuracy of WES variant calling in the pharmacogenes CYP2D6 and CYP2C19 by comparison with MiSeq® amplicon sequencing data (n = 36). This analysis revealed that the concordance rate between WES and MiSeq® was high, achieving 99.60% for variants that were called without exceeding the truth-sensitivity threshold (99%), defined during variant quality score recalibration. Beyond this threshold, the proportion of discordant calls increased markedly. Subsequently, we expanded our findings beyond CYP2D6 and CYP2C19 to include more genes genotyped by the iPLEX® ADME PGx Panel in the subset of twelve samples. WES performed well, agreeing with the genotyping panel in approximately 99% of the selected pass-filter variant calls. Overall, our results have demonstrated WES to be a promising approach for pharmacogenomic profiling, with an estimated error rate of lower than 1%. Quality filters, particularly variant quality score recalibration, are important for reducing the number of false variants. Future studies may benefit from examining the role of WES in the clinical setting for guiding drug therapy.

28 November 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
KIkConFab Investigators
kConFab Investigators
LJLucy C. de Jong
Lucy C. de Jong
SCSimone Cree
Simone Cree
VLVanessa Lattimore
Vanessa Lattimore
GWGeorge Wiggins
George Wiggins
LWLogan Walker
Logan Walker
Laboratory assays evaluating the effect of DNA sequence variants on BRCA1 mRNA splicing may contribute to classification by providing molecular evidence. However, our knowledge of normal and aberrant BRCA1 splicing events to date has been limited to data derived from assays targeting partial transcript sequences. This study explored the utility of nanopore sequencing to examine whole BRCA1 mRNA transcripts and to provide accurate categorisation of in-frame and out-of-frame splicing events. The exon structure of BRCA1 transcripts from a previously studied control lymphoblastoid cell line were assessed using MinION nanopore sequencing of long-range reverse transcriptase-PCR amplicons. Our study identified and characterised 32 complete BRCA1 isoforms, including 18 novel isoforms which showed skipping of multiple contiguous and/or non-contiguous exons. Furthermore, we show that known BRCA1 exon skipping events, such as Δ(9,10) and Δ21, can co-occur in a single transcript, with some isoforms containing four or more alternative splice junctions. Fourteen novel isoforms were formed entirely from a combination of previously identified alternative splice junctions, suggesting that the total number of BRCA1 isoforms might be lower than the number of splicing events reported previously. Our results highlight complexity in BRCA1 transcript structure that has not been described previously. This finding has key implications for predicting the translation frame of splicing transcripts, important for interpreting the clinical significance of spliceogenic variants. Future research is warranted to quantitatively assess full-length BRCA1 transcript levels, and to assess the application of nanopore sequencing for routine evaluation of potential spliceogenic variants.

28 July 2016 in FEBS Letters
Verified
Journal Article
Open access
PDF file
SCSimone L. Cree
Simone L. Cree
RFRayleen Fredericks
Rayleen Fredericks
AMAllison Miller
Allison Miller
FPF. Grant Pearce
F. Grant Pearce
VFVyacheslav Filichev
Vyacheslav Filichev
MKMartin Alexander Kennedy
Martin Alexander Kennedy
The DNA methyltransferase enzymes (DNMTs) catalyzing cytosine methylation do so at specific locations of the genome, although with some level of redundancy. The de novo methyltransferases DNMT3A and 3B play a vital role in methylating the genome of the developing embryo in regions devoid of methylation marks. The ability of DNMTs to colocalize at sites of DNA damage is suggestive that recognition of mispaired bases and unusual structures is inherent to the function of these proteins. We provide evidence for G‐quadruplex formation within imprinted gene promoters, and report high‐affinity binding of recombinant human DNMTs to such DNA G‐quadruplexes in vitro. These observations suggest a potential interaction of G‐quadruplexes with the DNA methylation machinery, which may be of epigenetic and biological significance.

27 September 2019 in Pharmacogenomics
Verified
Journal Article
Closed access
YLYusmiati Liau
Yusmiati Liau
Simran DS MaggoSimran DS Maggo
Simran DS Maggo
AMAllison L Miller
Allison L Miller
JPJohn F Pearson
John F Pearson
MKMartin Alexander Kennedy
Martin Alexander Kennedy
SCSimone L Cree
Simone L Cree
Aim: Long read sequencing offers the promise of overcoming some of the challenges in accurate genotyping of complex genes, along with the advantage of straightforward variant phasing. We have estab...

1 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAaron Stevens
Aaron Stevens
SSSelma Stuffrein-Roberts
Selma Stuffrein-Roberts
SCSimone L. Cree
Simone L. Cree
AGAndrew Gibb
Andrew Gibb
AMAllison L. Miller
Allison L. Miller
MKMartin Alexander Kennedy
Martin Alexander Kennedy
We observed apparent non-Mendelian behaviour of alleles when genotyping a region in a CpG island at the 5′ end of the maternally imprinted human MEST isoform. This region contains three single nucleotide polymorphisms (SNPs) in total linkage disequilibrium, such that only two haplotypes occur in the human population. Only one haplotype was detectable in each subject, never both, despite the use of multiple primers and several genotyping methods. We observed that this region contains motifs capable of forming several G-quadruplex structures. Circular dichroism spectroscopy and native polyacrylamide gel electrophoresis confirmed that at least three G-quadruplexes form in vitro in the presence of potassium ions, and one of these structures has a Tm of greater than 99°C in polymerase chain reaction (PCR) buffer. We demonstrate that it is the methylated maternal allele that is always lost during PCR amplification, and that formation of G-quadruplexes and presence of methylated cytosines both contributed to this phenomenon. This observed parent-of-origin specific allelic drop-out has important implications for analysis of imprinted genes in research and diagnostic settings.

8 July 2014 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SCSimone L. Cree
Simone L. Cree
MKMartin Alexander Kennedy
Martin Alexander Kennedy
G-quadruplexes are non-canonical secondary structures formed within nucleic acids that are involved in modulating cellular processes such as replication, gene regulation, recombination and epigenetics. Within genes, there is mounting evidence of G-quadruplex involvement in transcriptional and post transcriptional regulation. We report the presence of potential G-quadruplex motifs within relevant sites of some important pharmacogenes and discuss the possible implications of this on the function and expression of these genes. Appreciating the location and potential functions of these motifs may be of value when considering the impacts of some pharmacogenetic variants. G-quadruplexes are also the focus of drug development efforts in oncology and we highlight the broader pharmacological implications of treatment strategies that may target G-quadruplexes.